These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 26952039)

  • 1. Radiosensitization in esophageal squamous cell carcinoma: Effect of polo-like kinase 1 inhibition.
    Chen JL; Chen JP; Huang YS; Tsai YC; Tsai MH; Jaw FS; Cheng JC; Kuo SH; Shieh MJ
    Strahlenther Onkol; 2016 Apr; 192(4):260-8. PubMed ID: 26952039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polo-like Kinase Inhibitor Volasertib Exhibits Antitumor Activity and Synergy with Vincristine in Pediatric Malignancies.
    Abbou S; Lanvers-Kaminsky C; Daudigeos-Dubus E; LE Dret L; Laplace-Builhe C; Molenaar J; Vassal G; Geoerger B;
    Anticancer Res; 2016 Feb; 36(2):599-609. PubMed ID: 26851014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.
    Cholewa BD; Ndiaye MA; Huang W; Liu X; Ahmad N
    Cancer Lett; 2017 Jan; 385():179-187. PubMed ID: 27793694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human ATP-Binding Cassette Transporter ABCB1 Confers Resistance to Volasertib (BI 6727), a Selective Inhibitor of Polo-like Kinase 1.
    Wu CP; Hsieh CH; Hsiao SH; Luo SY; Su CY; Li YQ; Huang YH; Huang CW; Hsu SC
    Mol Pharm; 2015 Nov; 12(11):3885-95. PubMed ID: 26412161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells.
    Zhang Y; Du XL; Wang CJ; Lin DC; Ruan X; Feng YB; Huo YQ; Peng H; Cui JL; Zhang TT; Wang YQ; Zhang H; Zhan QM; Wang MR
    Gastroenterology; 2012 Mar; 142(3):521-530.e3. PubMed ID: 22108192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms.
    Nguyen T; Parker R; Hawkins E; Holkova B; Yazbeck V; Kolluri A; Kmieciak M; Rahmani M; Grant S
    Oncotarget; 2017 May; 8(19):31478-31493. PubMed ID: 28416758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-targeting PLK1 and mTOR induces synergistic inhibitory effects against esophageal squamous cell carcinoma.
    Liu TT; Yang KX; Yu J; Cao YY; Ren JS; Hao JJ; Pan BQ; Ma S; Yang LY; Cai Y; Wang MR; Zhang Y
    J Mol Med (Berl); 2018 Aug; 96(8):807-817. PubMed ID: 29959473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous PLK1 inhibition improves local tumour control after fractionated irradiation.
    Krause M; Kummer B; Deparade A; Eicheler W; Pfitzmann D; Yaromina A; Kunz-Schughart LA; Baumann M
    Radiother Oncol; 2013 Sep; 108(3):422-8. PubMed ID: 23891096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting polo-like kinase 1 enhances radiation efficacy for head-and-neck squamous cell carcinoma.
    Gerster K; Shi W; Ng B; Yue S; Ito E; Waldron J; Gilbert R; Liu FF
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):253-60. PubMed ID: 20394857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting PLKs as a therapeutic approach to well-differentiated thyroid cancer.
    Lin SF; Lin JD; Yeh CN; Huang YT; Chou TC; Wong RJ
    Endocr Relat Cancer; 2019 Aug; 26(8):727-738. PubMed ID: 31189135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A PLK1 kinase inhibitor enhances the chemosensitivity of cisplatin by inducing pyroptosis in oesophageal squamous cell carcinoma.
    Wu M; Wang Y; Yang D; Gong Y; Rao F; Liu R; Danna Y; Li J; Fan J; Chen J; Zhang W; Zhan Q
    EBioMedicine; 2019 Mar; 41():244-255. PubMed ID: 30876762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thioridazine Sensitizes Esophageal Carcinoma Cell Lines to Radiotherapy-Induced Apoptosis In Vitro and In Vivo.
    Li H; Juan L; Xia L; Wang Y; Bao Y; Sun G
    Med Sci Monit; 2016 Jul; 22():2624-34. PubMed ID: 27453171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53.
    Van den Bossche J; Deben C; De Pauw I; Lambrechts H; Hermans C; Deschoolmeester V; Jacobs J; Specenier P; Pauwels P; Vermorken JB; Peeters M; Lardon F; Wouters A
    Mol Oncol; 2019 May; 13(5):1196-1213. PubMed ID: 30859681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PLK1 is a critical determinant of tumor cell sensitivity to CPT11 and its inhibition enhances the drug antitumor efficacy in squamous cell carcinoma models sensitive and resistant to camptothecins.
    Zuco V; De Cesare M; Zaffaroni N; Lanzi C; Cassinelli G
    Oncotarget; 2015 Apr; 6(11):8736-49. PubMed ID: 25826089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PLK1-inhibition can cause radiosensitization or radioresistance dependent on the treatment schedule.
    Lund-Andersen C; Patzke S; Nähse-Kumpf V; Syljuåsen RG
    Radiother Oncol; 2014 Feb; 110(2):355-61. PubMed ID: 24502970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of sinomenine hydrochloride on radiosensitivity of esophageal squamous cell carcinoma cells.
    Fu S; Jin L; Gong T; Pan S; Zheng S; Zhang X; Yang T; Sun Y; Wang Y; Guo J; Hui B; Zhang X
    Oncol Rep; 2018 Apr; 39(4):1601-1608. PubMed ID: 29393484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non-Small-Cell Lung Cancer.
    Ellis PM; Leighl NB; Hirsh V; Reaume MN; Blais N; Wierzbicki R; Sadrolhefazi B; Gu Y; Liu D; Pilz K; Chu Q
    Clin Lung Cancer; 2015 Nov; 16(6):457-65. PubMed ID: 26100229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PLK1 blockade enhances therapeutic effects of radiation by inducing cell cycle arrest at the mitotic phase.
    Inoue M; Yoshimura M; Kobayashi M; Morinibu A; Itasaka S; Hiraoka M; Harada H
    Sci Rep; 2015 Oct; 5():15666. PubMed ID: 26503893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.
    Gorlick R; Kolb EA; Keir ST; Maris JM; Reynolds CP; Kang MH; Carol H; Lock R; Billups CA; Kurmasheva RT; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2014 Jan; 61(1):158-64. PubMed ID: 23956067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor.
    Van den Bossche J; Lardon F; Deschoolmeester V; De Pauw I; Vermorken JB; Specenier P; Pauwels P; Peeters M; Wouters A
    Med Res Rev; 2016 Jul; 36(4):749-86. PubMed ID: 27140825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.